Lawrence Evans Email & Phone Number

Seattle, Washington, Us

𝐀𝐋𝐏𝐍-101 (𝐚𝐜𝐚𝐳𝐢𝐜𝐨𝐥𝐜𝐞𝐩𝐭, 𝐝𝐮𝐚𝐥 𝐈𝐂𝐎𝐒 𝐚𝐧𝐝 𝐂𝐃28 𝐢𝐧𝐡𝐢𝐛𝐢𝐭𝐨𝐫) 𝐝𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭• Primary role in ALPN-101 drug development. Contributions include: lead identification; development of T follicular helper and germinal-center B cell reaction assay to demonstrate importance of inhibition of both ICOS- and CD28-mediated costimulation; development of cell-based functional assay for drug substance qualification and release; IND-enabling studies; development and performance of target saturation assays for preclinical and clinical samples.• Determined the ability of ALPN-101 to modulate cytokine response and/or gene expression from RA, PsA, SLE, SjS, MS, IBD and ILD patient samples; generated a robust data set for corporate business development / partnership activities• Phase 2 clinical trial in SLE is currently enrolling patients (partnership with Abbvie Inc.) 𝐀𝐋𝐏𝐍-303 (𝐩𝐨𝐯𝐞𝐭𝐚𝐜𝐢𝐜𝐞𝐩𝐭, 𝐝𝐮𝐚𝐥 𝐀𝐏𝐑𝐈𝐋 𝐚𝐧𝐝 𝐁𝐀𝐅𝐅 𝐢𝐧𝐡𝐢𝐛𝐢𝐭𝐨𝐫) 𝐝𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭• Primary role in ALPN-303 drug development. Contributions include: lead identification; development of a primary B cell assay to demonstrate impact of both APRIL and BAFF inhibition; IND-enabling studies.• Phase I healthy volunteer study completed. Clinical trials for autoimmune kidney diseases and autoimmune cytopenias initiated.𝐏𝐫𝐨𝐣𝐞𝐜𝐭 𝐓𝐞𝐚𝐦 𝐋𝐞𝐚𝐝 𝐨𝐟 𝐭𝐡𝐞 𝐅𝐮𝐧𝐜𝐭𝐢𝐨𝐧𝐚𝐥 𝐆𝐫𝐨𝐮𝐩• Developed essential assays to monitor the binding and activity of affinity matured proteins using primary T-cells and transformed cell lines• Identified clinical candidate leads affinity against several IgSF and TNFRSF therapeutic targets for autoimmune and oncology applications

Thousand Oaks, Ca, Us

Highly engaged and consistent top performer while working in two interdisciplinary departments. • Project leader for discovery programs for inflammation and cancer immunotherapy:• Championed an adaptive Chimeric Antigen Receptor (CAR) program for cancer immunotherapy • Key member of a comprehensive immuno-oncology task force focused on Bi-specific T-cell Engagers (BiTEs), Oncolytic viruses, CARs, checkpoint and co-stimulation targets • Researched an antibody-drug conjugate targeting T-cells for inflammatory diseases• Focused research on Idiopathic Pulmonary Fibrosis (IPF) and Scleroderma:• Lead investigator to identify and evaluate biomarkers to stratify IPF and Scleroderma

Thousand Oaks, Ca, Us

• Provided data and study reports to support IND filing of AMG80 (anti-CSF1R antibody), including mechanism of action studies. • Characterized tumor-associated macrophage and immune cell infiltrates from a variety of syngeneic and xenograft tumor models to monitor tumor immune microenvironment • Discovered a role for myeloid-derived suppressor cells in promoting tumor metastasis• In vivo lead for therapeutic antibody program specific for costimulatory TNF receptor superfamily member. • Identified lead clinical antibody and developed a novel in vivo assay to support mechanism of action studies. Perform internal studies (including PK/PD, toxicology) and coordinated studies with CROs

Focused research and development of Toll-like receptor agonists and antagonists for use as vaccine adjuvants and monotherapy applications: • Developed a model to evaluate WT-1 leukemia vaccine (antigenicity, formulation, and delivery) and provided critical data and input from exploratory phase through to human clinical trial design• Identified optimal formulations of TLR3, 4, 5, 7 and 9 individually or in combinations for induction of antigen-specific humoral and cellular responses. • Developed in vivo and in vitro assays for several infectious disease and cancer antigens Evaluated numerous vaccine delivery techniques and technologies:• Demonstrated improved delivery methods for DNA, viral, and protein based vaccines. Coordinated efforts between internal departments and external corporate and academic partners.

Focused research on adoptive immunotherapy of genetically modified T-cells:• Demonstrated expression and signaling of chimeric receptors in primary cells and celllines after improving transduction efficiencies• Generated and characterized antigen specific murine and human CTLAssayed humoral immune responses to recombinant Adeno-Associated Viral (AAV) vectors and transgenes from various in vivo studies:• Developed a high throughput assay to quantitate AAV neutralizing antibodies• Developed and validated ELISAs to measure antibody responses to transgenes from murine, macaque, rabbit and human sera or BAL samples